NCT06927635 Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
| NCT ID | NCT06927635 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Health Network, Toronto |
| Condition | Castrate Resistance Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 75 participants in total. It began in 2025-07-08 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * Able to provide informed consent * Histologic diagnosis of prostate adenocarcinoma * Castrate Resistance Prostate Cancer * Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions * Receiving any line of ST for \>3 months * All sites of OP disease are amenable to and can be safely treated with SBRT * ECOG performance status 0-3 Exclusion Criteria: * Evidence of spinal cord compression * Contraindication to radiotherapy
Contact & Investigator
Rachel Glicksman, MD
PRINCIPAL INVESTIGATOR
Princess Margaret Cancer Centre - University Health Network
Frequently Asked Questions
Who can join the NCT06927635 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 100 Years, studying Castrate Resistance Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06927635 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06927635 currently recruiting?
Yes, NCT06927635 is actively recruiting participants. Contact the research team at rachel.glicksman@uhn.ca for enrollment information.
Where is the NCT06927635 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06927635 clinical trial?
NCT06927635 is sponsored by University Health Network, Toronto. The principal investigator is Rachel Glicksman, MD at Princess Margaret Cancer Centre - University Health Network. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.